Manufacturers: Johnson & Johnson
靶向口服肽，选择性结合并阻断 IL-23 受体（IL-23R），抑制 IL-23 介导的信号传导
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
